An updated risk score to predict possible contrast-associated acute kidney injury (CA-AKI) among patients undergoing percutaneous coronary intervention (PCI) has been presented by Roxana Mehran (Icahn School of Medicine at Mount Sinai, New York, USA) at the American Heart Association’s Scientific Sessions 2021 (AHA 2021; 13–15 November; virtual).
The risk score, named “The Mehran-2 CA-AKI Risk Score,” builds upon an initial risk metric developed in 2004 and takes into account changes in practice surrounding PCI, including more advanced imaging techniques that require less toxic contrast agents, as well as improved stents.
“Although the incidence of CA-AKI has decreased over the past few years, it remains a significant complication of PCI and is associated with mortality, prolonged hospital stay, and increased medical costs. As the number of high-risk patients undergoing PCI increases every year, it is really crucial to risk-stratify these patients to optimise outcomes and minimise cardiorenal complications,” explains Mehran. “Simple measures can be taken around the time of procedure when a patient is identified to be at high risk of CA-AKI, and we hope this new score is widely adopted to enhance the care of patients and improve outcomes.”
To update the risk score, researchers looked at records of 30,000 patients who underwent PCI at The Mount Sinai Hospital from 2012 to 2020. All patients had documented creatinine tests—measuring how well kidneys are working and filtering waste from the blood—both pre procedure and 48 hours post procedure, as well as a one-year follow-up.
Mehran and her team created a predictor model identifying which patients are at highest risk of acute kidney injury based on baseline risk factors, which included diabetes, anaemia, congestive heart failure, advanced kidney disease, acute heart attack, and ST-segment elevation myocardial infarction (STEMI), or complete blockage of a major heart artery. Being older than 75 was also considered a risk factor. They assigned an individual score to each of those risk factors, then calculated patients’ overall risk score, putting them in specific groups: between 0-4 was “low risk,” 5‒9 was “moderate risk,” 10‒13 was “high risk,” and anything above 14 was “extremely high risk.”
By calculating patients’ risk score and figuring out what risk category they fit into, physicians can modify their periprocedural management approach to improve outcomes. This may include increasing hydration before PCI, administering statins, and minimizing the amount of contrast used during the procedure. The risk score may also help doctors increase monitoring before and after PCI, potentially doing additional blood tests. More specifically, if a patient is low risk, doctors can measure creatinine level once after the procedure, compared to high-risk patients who may need several measurements.
“Acute kidney injury after invasive procedures remains a mystery since it has such a robust adverse prognosis, yet we still don’t know of a clear responsible mechanism. Therefore, it remains a very challenging and interesting research field,” explains senior author George Dangas. “The fact that periprocedural events have only minor contribution to the overall predictive power makes this model even more important, as its risk assessment is accurately available before the start, and plans can be made very early on.”
“We plan to design clinical trials and incorporate this score to evaluate both external validation in predicting acute kidney injury but also clinical outcomes,” adds Mehran.